Robert L Kunka

US Patent:

20070122351, May 31, 2007

Filed:

Jan 30, 2007

Appl. No.:

11/668647

Inventors:

Robert KUNKA - Research Triangle Park NC, US
Tushar SHAH - Research Triangle Park NC, US

Assignee:

GLAXO GROUP LIMITED - Greenford

International Classification:

A61K 9/12
A61K 31/573

US Classification:

424045000, 514171000

Abstract:

A method for treating respiratory disorders by administrating by inhalation an effective amount of a β-receptor agonist, an acceptable amount of a corticosteriod, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteriod is fluticasone propionate or a solvate thereof. The combination of salmeterol, fluticasone proprionate, and HFA 134a may lower the risk of cardiac arrhythmias, sudden death, or hypercorticism that are sometimes associated with the simultaneous administration of a β-receptor agonist and an anti-inflammatory corticosteroid.

US Patent:

20070122352, May 31, 2007

Filed:

Jan 30, 2007

Appl. No.:

11/668664

Inventors:

Robert KUNKA - Research Triangle Park NC, US
Tushar SHAH - Research Triangle Park NC, US

Assignee:

GLAXO GROUP LIMITED - Greenford

International Classification:

A61K 31/573
A61K 9/12

US Classification:

424045000, 514171000

Abstract:

A method for treating respiratory disorders by administrating by inhalation an effective amount of a β-receptor agonist, an acceptable amount of a corticosteroid, and HFA 134, to a patient in need thereof, is disclosed. Preferably, the β-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteroid is fluticasone propionate or a solvate thereor. The combination of salmeterol, fluticasone proprionate, and HFA 134may lower the risk of cardiac arrhythmias, sudden death, or hypercorticism that are sometimes associated with the simultaneous administration of a β-receptor agonist and an anti-inflammatory corticosteroid.

US Patent:

20040197271, Oct 7, 2004

Filed:

Mar 5, 2004

Appl. No.:

10/472407

Inventors:

Robert Kunka - Durham NC, US
Tushar Shah - Flemington NJ, US

International Classification:

A61K031/573
A61L009/04

US Classification:

424/045000, 514/179000

Abstract:

A method for treating respiratory disorders by administrating by inhalation an effective amount of a -receptor agonist, an acceptable amount of a corticosteroid, and HFA 134, to a patient in need thereof, is disclosed. Preferably, the -receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteroid is fluticasone propionate or a solvate thereof. The combination of salmeterol, fluticasone proprionate, and HFA 134may lower the risk of cardiac arrhythmias, sudden death, or hypercorticism that are sometimes associated with the simultaneous administration of a -receptor agonist and an anti-inflammatory corticosteroid.